000167550 001__ 167550
000167550 005__ 20240917134515.0
000167550 0247_ $$2doi$$a10.1038/s41375-021-01172-x
000167550 0247_ $$2pmid$$apmid:33597728
000167550 0247_ $$2ISSN$$a0887-6924
000167550 0247_ $$2ISSN$$a1476-5551
000167550 0247_ $$2altmetric$$aaltmetric:100396477
000167550 037__ $$aDKFZ-2021-00415
000167550 041__ $$aeng
000167550 082__ $$a610
000167550 1001_ $$aAwwad, Mohamed H S$$b0
000167550 245__ $$aSelective elimination of immunosuppressive T cells in patients with multiple myeloma.
000167550 260__ $$aLondon$$bSpringer Nature$$c2021
000167550 3367_ $$2DRIVER$$aarticle
000167550 3367_ $$2DataCite$$aOutput Types/Journal article
000167550 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726573490_21166
000167550 3367_ $$2BibTeX$$aARTICLE
000167550 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167550 3367_ $$00$$2EndNote$$aJournal Article
000167550 500__ $$a2021 Sep;35(9):2602-2615
000167550 520__ $$aElimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma (MM). SLAMF7 expression associated with T cell exhaustion surface markers and exhaustion-related transcription factor signatures. T cells from patients with a high frequency of SLAMF7+CD8+ T cells exhibited decreased immunoreactivity towards the MART-1aa26-35*A27L antigen. A monoclonal anti-SLAMF7 antibody (elotuzumab) specifically depleted SLAMF7+CD8+ T cells in vitro and in vivo via macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Anti-SLAMF7 treatment of MM patients depleted suppressive T cells in peripheral blood. These data highlight SLAMF7 as a marker for suppressive CD8+ Treg and suggest that anti-SLAMF7 antibodies can be used to boost anti-tumoral immune responses in cancer patients.
000167550 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000167550 588__ $$aDataset connected to CrossRef, PubMed,
000167550 7001_ $$aMahmoud, Abdelrahman$$b1
000167550 7001_ $$aBruns, Heiko$$b2
000167550 7001_ $$0P:(DE-He78)d32743f5aa1b7577cded5ce1d6c153bf$$aEchchannaoui, Hakim$$b3$$udkfz
000167550 7001_ $$aKriegsmann, Katharina$$b4
000167550 7001_ $$aLutz, Raphael$$b5
000167550 7001_ $$0P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aRaab, Marc-Steffen$$b6$$udkfz
000167550 7001_ $$aBertsch, Uta$$b7
000167550 7001_ $$aMunder, Markus$$b8
000167550 7001_ $$aJauch, Anna$$b9
000167550 7001_ $$aWeisel, Katja$$b10
000167550 7001_ $$aMaier, Bettina$$b11
000167550 7001_ $$aWeinhold, Niels$$b12
000167550 7001_ $$aSalwender, Hans Jürgen$$b13
000167550 7001_ $$aEckstein, Volker$$b14
000167550 7001_ $$aHänel, Mathias$$b15
000167550 7001_ $$aFenk, Roland$$b16
000167550 7001_ $$aDürig, Jan$$b17
000167550 7001_ $$0P:(DE-He78)fc949170377b58098e46141d95c72661$$aBrors, Benedikt$$b18$$udkfz
000167550 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b19$$udkfz
000167550 7001_ $$00000-0002-7166-5232$$aMüller-Tidow, Carsten$$b20
000167550 7001_ $$aGoldschmidt, Hartmut$$b21
000167550 7001_ $$00000-0002-5596-2405$$aHundemer, Michael$$b22
000167550 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/s41375-021-01172-x$$n9$$p2602-2615$$tLeukemia$$v35$$x1476-5551$$y2021
000167550 909CO $$ooai:inrepo02.dkfz.de:167550$$pVDB
000167550 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d32743f5aa1b7577cded5ce1d6c153bf$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000167550 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000167550 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fc949170377b58098e46141d95c72661$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000167550 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000167550 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000167550 9130_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000167550 9141_ $$y2021
000167550 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2018$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-04
000167550 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bLEUKEMIA : 2018$$d2020-09-04
000167550 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x0
000167550 9201_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x1
000167550 9201_ $$0I:(DE-He78)B330-20160331$$kB330$$lAngewandte Bioinformatik$$x2
000167550 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x3
000167550 980__ $$ajournal
000167550 980__ $$aVDB
000167550 980__ $$aI:(DE-He78)FM01-20160331
000167550 980__ $$aI:(DE-He78)A360-20160331
000167550 980__ $$aI:(DE-He78)B330-20160331
000167550 980__ $$aI:(DE-He78)C060-20160331
000167550 980__ $$aUNRESTRICTED